Anavex Life Sciences Down Over 35%, on Pace for Largest Percent Decrease Since November 2020 -- Data Talk

Dow Jones11-15

Anavex Life Sciences Corp. ( AVXL ) is currently at $3.69, down $2.00 or 35.15%

 

--Would be lowest close since May 1, 2024, when it closed at $3.69

--On pace for largest percent decrease since Nov. 6, 2020, when it fell 35.22%

--Currently down two consecutive days; down 46.52% over this period

--Worst two day stretch since the two days ending July 28, 2016, when it fell 53.14%

--Down 49.38% this week; worst weekly performance on record (Based on available data back to April 13, 2006)

--Down 53.7% month-to-date

--Down 65.64% year-to-date; on pace for worst year since 2013, when it fell 68.35%

--Down 87.21% from its all-time closing high of $28.86 on June 28, 2021

--Down 50.44% from 52 weeks ago (Nov. 15, 2024), when it closed at $7.45

--Down 72.59% from its 52-week closing high of $13.46 on Jan. 7, 2025

--Would be a new 52-week closing low

--Traded as low as $2.86; lowest intraday level since April 8, 2020, when it hit $2.80

--Down 49.74% at today's intraday low; largest intraday percent decrease since Nov. 8, 2013, when it fell as much as 52.86%

 

All data as of 2:36:39 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

November 14, 2025 14:38 ET (19:38 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment